Sherlock Biosciences, Inc.

Sherlock Biosciences, Inc. is a for-profit corporate entity specializing in rapid, field-deployable molecular diagnostics based on CRISPR technology. Registered in SAM.gov since May 1, 2019, the company focuses on developing innovative diagnostic platforms for applications in human health, food security, and biodefense. Their core competency involves creating low-cost, point-of-need molecular testing solutions that can be deployed in various settings, including clinical, agricultural, and field environments, with a particular emphasis on developing tests that are accurate, portable, and accessible.

Through federal contract awards, Sherlock Biosciences has demonstrated expertise in developing advanced molecular diagnostic solutions for critical health challenges. Their most recent significant contract, valued at $9,374,751, was awarded by the Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services. This contract focuses on developing a low-cost, point-of-need molecular test for influenza A and B that can utilize self-collected swab specimens. Previously, the company has received contracts such as an Other Transaction Agreement with the Defense Threat Reduction Agency worth over $2 million, targeting ultra-fast, ultra-sensitive field diagnostic capabilities. These contracts are not typically set aside for specific business types, indicating the company's broad competitive capabilities.

Sherlock Biosciences has secured multiple federal grant awards that underscore its commitment to innovative diagnostic technologies. A notable grant from the National Institute of Allergy and Infectious Diseases provides $298,948 to develop a power-free molecular diagnostic device for detecting sexually transmitted infections, specifically Chlamydia trachomatis and Neisseria gonorrhoeae. Another grant from the Institute of Food Production and Sustainability supports the development of a CRISPR-based diagnostic for White Spot Syndrome Virus in shrimp farming, demonstrating the company's ability to apply its technological platform across different domains. These grants focus on creating diagnostic solutions that are accessible, accurate, and capable of addressing critical screening needs in human health and agricultural settings, with an emphasis on developing technologies that can be used in point-of-need or at-home environments.